**Proteins** 

# A-1210477

Cat. No.: HY-12468 CAS No.: 1668553-26-1 Molecular Formula:  $C_{46}H_{55}N_{7}O_{7}S$ Molecular Weight: 850.04

Target: Bcl-2 Family; Apoptosis

Pathway: **Apoptosis** 

Storage: Powder -20°C 3 years

2 years

-80°C In solvent 2 years

> -20°C 1 year

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 10 mg/mL (11.76 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.1764 mL	5.8821 mL	11.7642 mL
	5 mM	0.2353 mL	1.1764 mL	2.3528 mL
	10 mM	0.1176 mL	0.5882 mL	1.1764 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.18 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1 mg/mL (1.18 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (1.18 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description A-1210477 is a potent and selective inhibitor of MCL-1 with a  $K_i$  of 0.45 nM $^{[1]}$ . A-1210477 specifically binds MCL-1 and promotes apoptosis of cancer cells in an MCL-1-dependent manner<sup>[2]</sup>.

IC<sub>50</sub> & Target

Bcl-2 Mcl-1 0.45 nM (Ki) 132 nM (Ki) Bfl-1 660 nM (Ki)

Bcl-W 2280 nM (Ki)

**Apoptosis** 

#### In Vitro

A-1210477 (10  $\mu$ M) reduces the amount of BIM co-immunoprecipitated with MCL-1 antibody, and triggers MCL-1 elevation in a variety of cancer cell lines, including the breast cancer cell line HCC-1806. A-1210477 inhibits MCL-1-NOXA interactions with an IC<sub>50</sub> of approximately 1  $\mu$ M, while having no effect on BCL-2-BIM or BCL-XL-BCL-XS interactions. The NSCLC cell lines H2110 and H23 are sensitive to A-1210477 with cell viability IC<sub>50</sub><10  $\mu$ M, confirming that A-1210477 can kill MCL-1-dependent cell lines<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **PROTOCOL**

## Kinase Assay [1]

TR-FRET-binding affinity assays are performed for BCL-2, BCL-XL, and MCL-1 in 4.52 mM monobasic potassium phosphate, 15.48 mM dibasic potassium phosphate, 1 mM sodium EDTA, 0.05% Pluronic F-68 detergent, 50 mM sodium chloride, and 1 mM DTT (pH 7.5) for BCL-XL.6 For MCL-1 assays, GST-tagged MCL-1 (1 nM) is mixed with 100 nM f-Bak, 1 nM Tb-labeled anti-GST antibody, and compound at room temperature (RT) for 60 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-GST antibody) emission filters. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## Cell Assay [1]

Adherent cell lines are seeded at 50 000 cells per well in 96-well plates and treated for 48 h with compounds diluted in half-log steps starting at 30  $\mu$ M and ending at 0.001  $\mu$ M. Multiple myeloma cell lines are seeded at 15 000-20 000 cells per well and treated similarly. Effects on proliferation and viability are determined using CellTiter-Glo reagent from Promega according to the manufacturer's instructions. IC<sub>50</sub> values are determined by non-linear regression analysis of the concentration response data.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **CUSTOMER VALIDATION**

- Cell Death Differ. 2019 Mar;26(3):470-486.
- J Pineal Res. 2024 Jan 31.
- Cell Death Dis. 2021 Aug 12;12(8):789.
- Cell Death Dis. 2020 Nov 15;11(11):982.
- Biochem Pharmacol. 2022 May;199:115017.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Leverson JD, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015 Jan 15;6:e1590.

[2]. Qing Wang, et al. A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML. Oncol Lett. 2019 Nov;18(5):5481-5489.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA